Strategic Advisory Board
David Darst joined Rgenix as CEO in 2013 with a mission to develop the world's first cancer therapies designed specifically to target cancer metastasis. Mr. Darst is a former venture capitalist with OrbiMed, where he focused on Venture Capital and PIPE investments in biotechnology, diagnostics, and life science tools companies. Mr. Darst is a co-founder of two biotechnology companies, Potentia Pharmaceuticals and Medicine in Need, with treatments in development for Age-Related Macular Degeneration and Tuberculosis respectively. He also co-founded an internet health company, Firefly Health, and worked as a summer associate with McKinsey & Company, Pfizer, and Millennium Pharmaceuticals. He is a founding investor of Good Start Genetics, and is currently a Director of Apellis Pharmaceuticals and SHC Media, and sits on the Rockefeller Advisory Council and Mount Sinai Icahn Institute Advisory Board. Mr. Darst earned an A.B. degree cum laude from Harvard College and an M.B.A. from Harvard Business School.
Scientific Advisory Board
Legal Notice ©2002-2014 Provectus Biopharmaceuticals, Inc.